256 related articles for article (PubMed ID: 19754919)
1. Plasma buprenorphine concentrations after the application of a 70 microg/h transdermal patch in dogs. Preliminary report.
Andaluz A; Moll X; Ventura R; Abellán R; Fresno L; García F
J Vet Pharmacol Ther; 2009 Oct; 32(5):503-5. PubMed ID: 19754919
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs.
Andaluz A; Moll X; Abellán R; Ventura R; Carbó M; Fresno L; García F
Vet J; 2009 Sep; 181(3):299-304. PubMed ID: 18467137
[TBL] [Abstract][Full Text] [Related]
3. Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs.
Pieper K; Schuster T; Levionnois O; Matis U; Bergadano A
Vet J; 2011 Mar; 187(3):335-41. PubMed ID: 20206560
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine and the transdermal system: the ideal match in pain management.
Budd K
Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of buprenorphine following intravenous administration in dogs.
Krotscheck U; Boothe DM; Little AA
Am J Vet Res; 2008 Jun; 69(6):722-7. PubMed ID: 18518651
[TBL] [Abstract][Full Text] [Related]
6. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine.
Filitz J; Griessinger N; Sittl R; Likar R; Schüttler J; Koppert W
Eur J Pain; 2006 Nov; 10(8):743-8. PubMed ID: 16426877
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
9. Disposition of transdermally administered fentanyl in dogs.
Kyles AE; Papich M; Hardie EM
Am J Vet Res; 1996 May; 57(5):715-9. PubMed ID: 8723888
[TBL] [Abstract][Full Text] [Related]
10. Comparison of subcutaneous and transdermal administration of buprenorphine for pre-emptive analgesia in dogs undergoing elective ovariohysterectomy.
Moll X; Fresno L; García F; Prandi D; Andaluz A
Vet J; 2011 Jan; 187(1):124-8. PubMed ID: 20056555
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.
Carroll GL; Hooper RN; Boothe DM; Hartsfield SM; Randoll LA
Am J Vet Res; 1999 Aug; 60(8):986-91. PubMed ID: 10451210
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of buprenorphine after intravenous administration in the mouse.
Yu S; Zhang X; Sun Y; Peng Y; Johnson J; Mandrell T; Shukla AJ; Laizure SC
J Am Assoc Lab Anim Sci; 2006 May; 45(3):12-6. PubMed ID: 16642964
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fentanyl transdermal patches in rabbits: blood concentrations and physiologic response.
Foley PL; Henderson AL; Bissonette EA; Wimer GR; Feldman SH
Comp Med; 2001 Jun; 51(3):239-44. PubMed ID: 11924779
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs.
Abbo LA; Ko JC; Maxwell LK; Galinsky RE; Moody DE; Johnson BM; Fang WB
Vet Ther; 2008; 9(2):83-93. PubMed ID: 18597246
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of buprenorphine in healthy, lactating goats.
Ingvast-Larsson C; Svartberg K; Hydbring-Sandberg E; Bondesson U; Olsson K
J Vet Pharmacol Ther; 2007 Jun; 30(3):249-56. PubMed ID: 17472657
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse.
Davis JL; Messenger KM; LaFevers DH; Barlow BM; Posner LP
J Vet Pharmacol Ther; 2012 Feb; 35(1):52-8. PubMed ID: 21392040
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
Freise KJ; Newbound GC; Tudan C; Clark TP
J Vet Pharmacol Ther; 2012 Aug; 35 Suppl 2():27-33. PubMed ID: 22731773
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
[TBL] [Abstract][Full Text] [Related]
20. Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers.
Priestley T; Chappa AK; Mould DR; Upton RN; Shusterman N; Passik S; Tormo VJ; Camper S
Pain Med; 2018 Oct; 19(10):1988-1996. PubMed ID: 29036723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
